Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

Market open

/zigman2/quotes/207821052/composite

$

100.89

Change

-9.06 -8.24%

Volume

Volume 627,126

Dec 3, 2021, 2:40 p.m.

Real time quotes

/zigman2/quotes/207821052/composite

Previous close

$ 109.95

$ 100.89

Change

-9.06 -8.24%

Day low

Day high

$100.66

$110.00

Open
Open: 109.26

52 week low

52 week high

$40.10

$202.73

Open

Market cap

$8.18B

Average volume

725,187

P/E ratio

N/A

Rev. per Employee

$185,878

EPS

-3.36

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  2. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  3. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    6:37 a.m. Sept. 27, 2021

    - Barron's Online

  4. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    6:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  5. Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI

    4:58 a.m. Aug. 6, 2021

    - Tomi Kilgore

  6. The Best and Worst Biopharma Stock Performers So Far in 2021

    10:32 a.m. June 30, 2021

    - Barron's Online

  7. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform

    6:37 a.m. June 29, 2021

    - Tonya Garcia

  8. Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy

    10:24 a.m. June 28, 2021

    - Tonya Garcia

  9. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    8:21 a.m. June 30, 2021

    - Barron's Online

  10. First In-Vivo Gene Editing Data Look Good for Intellia

    7:40 a.m. June 28, 2021

    - Barron's Online

  11. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    7:32 a.m. May 21, 2021

    - Barron's Online

  12. Biotech stocks are a buy — especially these 18 picks

    1:02 p.m. March 13, 2021

    - Michael Brush

  13. Intellia Therapeutics price target raised to $106 from $39 at Raymond James

    7:50 a.m. Jan. 8, 2021

    - Tonya Garcia

  14. The 12 Most Overpriced Stocks in America

    7:48 a.m. Dec. 28, 2020

    - Barron's Online

  15. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. Intellia Stock: Setting Up For Success

    10:49 a.m. Nov. 29, 2021

    - Seeking Alpha

  2. Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?

    11:31 a.m. Nov. 21, 2021

    - Motley Fool

  3. Intellia: A Step Closer To A Life-Changing Cure

    9:05 a.m. Nov. 21, 2021

    - Seeking Alpha

  4. IDNA: Healthcare Dashboard For November

    4:12 a.m. Nov. 19, 2021

    - Seeking Alpha

  5. Intellia Therapeutics EPS misses by $0.11, misses on revenue

    7:32 a.m. Nov. 4, 2021

    - Seeking Alpha

  6. Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

    6:20 a.m. Nov. 4, 2021

    - Zacks.com

  7. Notable earnings before Thursday's open

    11:55 a.m. Nov. 3, 2021

    - Seeking Alpha

  8. Intellia Therapeutics Q3 2021 Earnings Preview

    10:29 a.m. Nov. 3, 2021

    - Seeking Alpha

  9. Loading more headlines...
/news/pressrelease/company/us/ntla

Press Releases on NTLA

  1. Why Regeneron, Intellia Therapeutics On Sale

    5:43 a.m. Oct. 14, 2021

    - Baystreet.ca

  2. IWM, UTSL: Big ETF Inflows

    9:47 a.m. Sept. 28, 2021

    - MarketNewsVideo.com

  3. Loading more headlines...

Rates »

Link to MarketWatch's Slice.